Glenn Rosen

Publication Details

  • PG490-88, a derivative of triptolide, blocks bleomycin-induced lung fibrosis AMERICAN JOURNAL OF PATHOLOGY Krishna, G., Liu, K. L., Shigemitsu, H., Gao, M. X., Raffin, T. A., Rosen, G. D. 2001; 158 (3): 997-1004

    Abstract:

    In this study we evaluate the antifibrotic properties of PG-490-88, a water-soluble derivative of triptolide. Triptolide is an oxygenated diterpene that is derived from a traditional Chinese herb that has potent immunosuppressive and antitumor activity. We used the intratracheal bleomycin mouse model and found that PG490-88 inhibits fibrosis in the bleomycin group when given the same day or 5 days after bleomycin. PG490-88 also markedly reduced the number of myofibroblasts in the bleomycin treatment group. An enzyme-linked immunosorbent assay of transforming growth factor (TGF)-beta in the bronchoalveolar lavage fluid showed a significant decrease in TGF-beta in the PG490-88-treated groups compared to the bleomycin-treated group. Additionally, triptolide blocked bleomycin-induced increase in TGF-beta mRNA in cultured normal human lung fibroblasts. The efficacy of PG490-88 when administered late after bleomycin installation suggests a potential role in the treatment of idiopathic pulmonary fibrosis.

    View details for Web of Science ID 000167411100023

    View details for PubMedID 11238047

Stanford Medicine Resources:

Footer Links: